Diagnostic Center | July 01, 2025
Moderna announces promising efficacy results from mRNA flu vaccine trial
mRNA-1010 demonstrated superior relative vaccine efficacy
mRNA-1010 demonstrated superior relative vaccine efficacy
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
